The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors

Andrology

Volumn 2, Issue 1, 2014, Pages 45-50

  Sung, H H ^a   Ahn, J S ^a   Kim, J J ^a   Choo, S H ^a   Han, D H ^a   Lee, S W ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Erectile dysfunction; Intracavernosal injection; PDE5 inhibitor

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FOLLOW UP; HUMAN; KOREA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PAINFUL ERECTION; PATIENT SATISFACTION; PENIS DISEASE; PENIS ERECTION; PENIS PROSTHESIS; PRIORITY JOURNAL; PROLONGED ERECTION; PROSTATECTOMY; RIGIDITY; RISK FACTOR; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; TELEPHONE INTERVIEW; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; UROLOGICAL THERAPEUTIC DEVICE; VACUUM DEVICE;

ERECTILE DYSFUNCTION; INTRACAVERNOSAL INJECTION; PDE5 INHIBITOR;

ALPROSTADIL; COITUS; ERECTILE DYSFUNCTION; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PAPAVERINE; PATIENT SATISFACTION; PENILE ERECTION; PHENTOLAMINE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; SELF ADMINISTRATION; SULFONES; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 84890827564     PISSN: 20472919     EISSN: 20472927     Source Type: Journal    
DOI: 10.1111/j.2047-2927.2013.00155.x     Document Type: Article

References (23)

1. Bennett AH, Carpenter AJ & Barada JH. (1991) An improved vasoactive drug combination for a pharmacological erection program. J Urol 146, 1564-1565.
2. Brindley GS. (1983) Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence. Br J Psychiatry 143, 332-337.
3. Brock G, Tu LM & Linet OI. (2001) Return of spontaneous erection during long-term intracavernosal alprostadil (Caverject) treatment. Urology 57, 536-541.
4. Costa P & Potempa AJ. (2012) Intraurethral alprostadil for erectile dysfunction: a review of the literature. Drugs 72, 2243-2254.
5. Domes T, Chung E, DeYoung L, MacLean N, Al-Shaiji T & Brock G. (2012) Clinical outcomes of intracavernosal injection in postprostatectomy patients: a single-center experience. Urology 79, 150-155.
6. Eardley I, Donatucci C, Corbin J, El-Meliegy A, Hatzimouratidis K, McVary K et al. (2010) Pharmacotherapy for erectile dysfunction. J Sex Med 7, 524-540.
7. Fallon B. (1995) Intracavernous injection therapy for male erectile dysfunction. Urol Clin North Am 22, 833-845.
8. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ & McKinlay JB. (1994a) Construction of a surrogate variable for impotence in the Massachusetts Male Aging Study. J Clin Epidemiol 47, 457-467.
9. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ & McKinlay JB. (1994b) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151, 54-61.
10. Gheorghiu S, Godschalk M, Gentili A & Mulligan T. (1996) Quality of life in patients using self-administered intracavernous injections of prostaglandin E1 for erectile dysfunction. J Urol 156, 80-81.
11. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD & Wicker PA. (1998) Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 338, 1397-1404.
12. Hatzimouratidis K & Hatzichristou DG. (2005) A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs 65, 1621-1650.
13. Hsiao W, Bennett N, Guhring P, Narus J & Mulhall JP. (2011) Satisfaction profiles in men using intracavernosal injection therapy. J Sex Med 8, 512-517.
14. Lehmann K, Casella R, Blochlinger A & Gasser TC. (1999) Reasons for discontinuing intracavernous injection therapy with prostaglandin E1 (alprostadil). Urology 53, 397-400.
15. Linet OI & Ogrinc FG. (1996) Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med 334, 873-877.
16. Melnik T, Soares BG & Nasello AG. (2008) The effectiveness of psychological interventions for the treatment of erectile dysfunction: systematic review and meta-analysis, including comparisons to sildenafil treatment, intracavernosal injection, and vacuum devices. J Sex Med 5, 2562-2574.
17. Mulhall JP, Jahoda AE, Cairney M, Goldstein B, Leitzes R, Woods J et al. (1999) The causes of patient dropout from penile self-injection therapy for impotence. J Urol 162, 1291-1294.
18. National Institutes of Health (1992) Impotence. NIH Consens Statement 10, 1-33.
19. Porst H. (1996) The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 155, 802-815.
20. Porst H. (2000) Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction. Int J Impot Res 12(Suppl. 4), S91-S100.
21. Porst H, Buvat J, Meuleman E, Michal V & Wagner G. (1998) Intracavernous Alprostadil Alfadex - an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study. Int J Impot Res 10, 225-231.
22. Purvis K, Egdetveit I & Christiansen E. (1999) Intracavernosal therapy for erectile failure-impact of treatment and reasons for drop-out and dissatisfaction. Int J Impot Res 11, 287-299.
23. Raina R, Lakin MM, Thukral M, Agarwal A, Ausmundson S, Montague DK et al. (2003) Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int J Impot Res 15, 318-322.